Day One Biopharmaceuticals Key Executives
This section highlights Day One Biopharmaceuticals's key executives, including their titles and compensation details.
Find Contacts at Day One Biopharmaceuticals
(Showing 0 of )
Day One Biopharmaceuticals Earnings
This section highlights Day One Biopharmaceuticals's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-02-26 | N/A | N/A |
| Read Transcript | Q3 | 2024 | 2024-10-30 | $-0.41 | $0.38 |
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
$7.74
Stock Price
$784.48M
Market Cap
181
Employees
South San Francisco, CA
Location
Financial Statements
Access annual & quarterly financial statements for Day One Biopharmaceuticals, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $131.16M | $- | $- | $- | $- |
| Cost of Revenue | $5.28M | $383.00K | $531.00K | $199.00K | $155.00K |
| Gross Profit | $125.88M | $-383.00K | $-531.00K | $-199.00K | $-155.00K |
| Gross Profit Ratio | 95.98% | - | - | - | - |
| Research and Development Expenses | $227.70M | $130.52M | $85.62M | $43.58M | $9.10M |
| General and Administrative Expenses | $- | $75.54M | $61.29M | $29.16M | $4.68M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $115.45M | $75.54M | $61.29M | $29.16M | $4.68M |
| Other Expenses | $- | $1 | $-18.00K | $-15.00K | $-31.00K |
| Operating Expenses | $343.15M | $206.06M | $146.91M | $72.74M | $13.78M |
| Cost and Expenses | $348.43M | $206.06M | $146.91M | $72.74M | $13.78M |
| Interest Income | $- | $17.19M | $4.75M | $4.00K | $30 |
| Interest Expense | $- | $- | $4.75M | $4.00K | $30.00K |
| Depreciation and Amortization | $- | $383.00K | $531.00K | $199.00K | $155.00K |
| EBITDA | $-217.27M | $-206.06M | $-141.65M | $-72.56M | $-43.66M |
| EBITDA Ratio | -165.65% | - | - | - | - |
| Operating Income | $-217.27M | $-206.06M | $-146.91M | $-72.74M | $-13.78M |
| Operating Income Ratio | -165.65% | - | - | - | - |
| Total Other Income Expenses Net | $128.92M | $17.15M | $4.73M | $-11.00K | $-30.06M |
| Income Before Tax | $-88.35M | $-188.92M | $-142.18M | $-72.75M | $-43.84M |
| Income Before Tax Ratio | -67.36% | - | - | - | - |
| Income Tax Expense | $-7.14M | $- | $-10.01M | $-2.31M | $-3.34M |
| Net Income | $-95.50M | $-188.92M | $-132.18M | $-70.44M | $-40.51M |
| Net Income Ratio | -72.81% | - | - | - | - |
| EPS | $-1.02 | $-2.37 | $-2.02 | $-1.14 | $-0.65 |
| EPS Diluted | $-1.02 | $-2.37 | $-2.02 | $-1.14 | $-0.65 |
| Weighted Average Shares Outstanding | 93.62M | 79.77M | 65.47M | 61.95M | 61.93M |
| Weighted Average Shares Outstanding Diluted | 93.62M | 79.77M | 65.47M | 61.95M | 61.93M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $29.21M | $93.76M | $8.19M | $- | $560.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cost of Revenue | $2.98M | $1.59M | $707.00K | $116.00K | $280.00K | $99.00K | $92.00K | $89.00K | $180.00K | $165.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Gross Profit | $26.23M | $92.17M | $7.49M | $-116.00K | $280.00K | $-99.00K | $-92.00K | $-89.00K | $-180.00K | $-165.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Gross Profit Ratio | 89.79% | 98.30% | 91.37% | - | 50.00% | - | - | - | - | - | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $61.82M | $33.56M | $92.11M | $40.21M | $37.35M | $33.16M | $32.18M | $27.83M | $26.02M | $22.04M | $22.56M | $15.00M | $43.58M | $9.85M | $9.91M | $12.63M | $4.17M | $2.54M | $1.44M | $961.00K |
| General and Administrative Expenses | $- | $- | $30.19M | $26.56M | $22.17M | $18.27M | $17.07M | $18.03M | $16.72M | $17.66M | $14.16M | $12.74M | $29.16M | $9.39M | $5.53M | $3.45M | $1.98M | $1.02M | $872.00K | $808.00K |
| Selling and Marketing Expenses | $- | $- | $- | $-116.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $29.73M | $28.97M | $30.19M | $26.44M | $22.17M | $18.27M | $17.07M | $18.03M | $16.72M | $17.66M | $14.16M | $12.74M | $29.16M | $9.39M | $5.53M | $3.45M | $1.98M | $1.02M | $872.00K | $808.00K |
| Other Expenses | $- | $- | $107.99M | $-10.00K | $-18.00K | $-3.00K | $-15.00K | $-4.00K | $-26.00K | $9.00K | $- | $-1.00K | $14.00K | $7.00K | $-27.00K | $-8.00K | $-26.00K | $-1.00K | $-90.00K | $-2.00K |
| Operating Expenses | $91.56M | $62.53M | $122.29M | $66.65M | $59.52M | $51.44M | $49.25M | $45.85M | $42.74M | $39.70M | $36.72M | $27.75M | $72.74M | $19.24M | $15.44M | $16.09M | $6.14M | $3.56M | $2.31M | $1.77M |
| Cost and Expenses | $94.54M | $64.12M | $123.00M | $66.77M | $59.52M | $51.44M | $49.25M | $45.85M | $42.74M | $39.70M | $36.72M | $27.75M | $72.74M | $19.24M | $15.44M | $16.09M | $6.14M | $3.56M | $2.31M | $1.77M |
| Interest Income | $- | $- | $3.96M | $- | $- | $5.29M | $3.41M | $- | $2.66M | $1.90M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Interest Expense | $- | $- | $- | $- | $- | $- | $- | $- | $2.66M | $1.90M | $- | $2.00K | $4.00K | $6.00K | $7.00K | $7.00K | $8.00K | $9.00K | $10.00K | $3.00K |
| Depreciation and Amortization | $759.00K | $- | $408.00K | $116.00K | $103.00K | $99.00K | $92.00K | $89.00K | $180.00K | $165.00K | $133.00K | $53.00K | $5.00K | $50.00K | $49.00K | $49.00K | $49.00K | $46.00K | $46.00K | $14.00K |
| EBITDA | $-64.57M | $29.64M | $-114.49M | $-66.77M | $-59.50M | $-51.44M | $-49.25M | $-45.85M | $-42.73M | $-39.70M | $-36.59M | $-27.75M | $-21.97M | $-19.18M | $-15.39M | $-16.04M | $-35.54M | $-3.79M | $-2.35M | $-1.98M |
| EBITDA Ratio | -221.08% | 31.61% | -1397.63% | - | -10625.71% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | $-65.33M | $29.64M | $-114.81M | $-66.77M | $-59.52M | $-51.44M | $-49.25M | $-45.85M | $-42.74M | $-39.70M | $-36.72M | $-27.75M | $-121.93M | $-19.24M | $-15.44M | $-16.09M | $-6.14M | $-3.56M | $-2.31M | $-1.77M |
| Operating Income Ratio | -223.68% | 31.61% | -1401.45% | - | -10628.04% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Other Income Expenses Net | $6.09M | $6.52M | $111.95M | $4.35M | $5.01M | $5.29M | $3.39M | $3.46M | $2.63M | $1.90M | $189.00K | $1.00K | $37.00K | $1.00K | $-34.00K | $-15.00K | $-29.46M | $-281.00K | $-100.00K | $-223.00K |
| Income Before Tax | $-59.24M | $36.16M | $-2.85M | $-62.41M | $-54.51M | $-46.15M | $-45.86M | $-42.39M | $-40.11M | $-37.80M | $-36.53M | $-27.75M | $-119.83M | $-19.24M | $-15.47M | $-16.10M | $-35.60M | $-3.84M | $-2.41M | $-1.99M |
| Income Before Tax Ratio | -202.82% | 38.56% | -34.85% | - | -9734.11% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Income Tax Expense | $6.47M | $-882.00K | $1.55M | $72.72K | $10.52M | $-99.00K | $-3.41M | $-7.02M | $-5.29M | $-3.80M | $-189.00K | $-3.00K | $4.00K | $7.00K | $-27.00K | $-920.00K | $-1.24M | $-1.01M | $-639.00K | $-456.00K |
| Net Income | $-65.71M | $37.04M | $-4.41M | $-62.41M | $-54.51M | $-46.15M | $-45.86M | $-35.38M | $-34.81M | $-34.00M | $-36.53M | $-27.74M | $-119.83M | $-19.24M | $-14.28M | $-15.18M | $-34.38M | $-2.82M | $-1.76M | $-1.53M |
| Net Income Ratio | -224.99% | 39.50% | -53.80% | - | -9734.11% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS | $-0.70 | $0.38 | $-0.05 | $-0.72 | $-0.62 | $-0.54 | $-0.61 | $-0.49 | $-0.47 | $-0.48 | $-0.60 | $-0.48 | $-1.93 | $-0.31 | $-0.23 | $-0.25 | $-0.56 | $-0.05 | $-0.03 | $-0.02 |
| EPS Diluted | $-0.70 | $0.38 | $-0.05 | $-0.72 | $-0.62 | $-0.54 | $-0.61 | $-0.49 | $-0.47 | $-0.48 | $-0.60 | $-0.48 | $-1.93 | $-0.31 | $-0.23 | $-0.25 | $-0.56 | $-0.05 | $-0.03 | $-0.02 |
| Weighted Average Shares Outstanding | 93.62M | 96.62M | 87.12M | 86.68M | 87.23M | 85.95M | 74.96M | 71.97M | 73.46M | 71.01M | 60.76M | 58.38M | 61.95M | 61.93M | 61.93M | 61.93M | 61.93M | 61.93M | 61.93M | 61.93M |
| Weighted Average Shares Outstanding Diluted | 93.62M | 96.94M | 87.12M | 86.68M | 87.23M | 85.95M | 74.96M | 71.97M | 73.46M | 71.01M | 60.76M | 58.38M | 61.95M | 61.93M | 61.93M | 61.93M | 61.93M | 61.93M | 61.93M | 61.93M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $124.97M | $230.78M | $85.26M | $284.31M | $43.73M |
| Short Term Investments | $406.75M | $135.56M | $257.01M | $- | $- |
| Cash and Short Term Investments | $531.72M | $366.35M | $342.27M | $284.31M | $43.73M |
| Net Receivables | $13.88M | $- | $- | $- | $- |
| Inventory | $3.32M | $- | $- | $- | $- |
| Other Current Assets | $13.41M | $8.93M | $5.61M | $5.06M | $1.34M |
| Total Current Assets | $562.33M | $375.27M | $347.87M | $289.37M | $45.07M |
| Property Plant Equipment Net | $4.71M | $560.00K | $719.00K | $284.00K | $483.00K |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $15.63M | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $15.63M | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $121.00K | $214.00K | $469.00K | $169.00K | $107.00K |
| Total Non-Current Assets | $20.46M | $774.00K | $1.19M | $453.00K | $590.00K |
| Other Assets | $- | $- | $- | $-0 | $- |
| Total Assets | $582.79M | $376.05M | $349.06M | $289.82M | $45.66M |
| Account Payables | $3.26M | $2.58M | $260.00K | $1.74M | $202.00K |
| Short Term Debt | $20.00K | $408.00K | $810.00K | $408.00K | $198.00K |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $1.55M | $- | $- | $6.61M | $1.57M |
| Other Current Liabilities | $68.61M | $26.52M | $15.54M | $6.50M | $1.60M |
| Total Current Liabilities | $73.45M | $29.51M | $16.61M | $8.66M | $2.00M |
| Long Term Debt | $2.59M | $- | $408.00K | $16.00K | $204.00K |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $3.99M | $- | $- | $- | $91.96M |
| Total Non-Current Liabilities | $6.59M | $- | $408.00K | $16.00K | $92.17M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $80.04M | $29.51M | $17.02M | $8.67M | $94.16M |
| Preferred Stock | $- | $- | $- | $- | $5.70M |
| Common Stock | $10.00K | $9.00K | $7.00K | $6.00K | $2.00M |
| Retained Earnings | $-554.08M | $-458.58M | $-269.67M | $-127.49M | $-56.84M |
| Accumulated Other Comprehensive Income Loss | $84.00K | $9.00K | $-71.00K | $0 | $637 |
| Other Total Stockholders Equity | $1.06B | $805.11M | $601.77M | $408.63M | $92.60M |
| Total Stockholders Equity | $502.75M | $346.54M | $-269.67M | $-127.49M | $-54.20M |
| Total Equity | $502.75M | $346.54M | $-269.67M | $162.33M | $-48.50M |
| Total Liabilities and Stockholders Equity | $582.79M | $376.05M | $-252.65M | $-118.81M | $45.66M |
| Minority Interest | $- | $- | $- | $289.82M | $5.70M |
| Total Liabilities and Total Equity | $582.79M | $376.05M | $-252.65M | $-118.81M | $45.66M |
| Total Investments | $406.75M | $135.56M | $257.01M | $- | $- |
| Total Debt | $2.60M | $408.00K | $813.00K | $220.00K | $402.00K |
| Net Debt | $-122.37M | $-230.38M | $-84.45M | $-284.09M | $-43.33M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $124.97M | $422.76M | $239.62M | $270.39M | $230.78M | $241.18M | $189.21M | $49.27M | $85.26M | $120.86M | $388.88M | $262.73M | $284.31M | $297.16M | $310.00M | $154.87M | $43.73M | $- |
| Short Term Investments | $406.75M | $135.62M | $122.25M | $47.55M | $135.56M | $164.36M | $253.67M | $268.91M | $257.01M | $253.48M | $5.99M | $- | $- | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $531.72M | $558.38M | $361.87M | $317.94M | $366.35M | $405.54M | $442.88M | $318.18M | $342.27M | $374.34M | $394.86M | $262.73M | $284.31M | $297.16M | $310.00M | $154.87M | $43.73M | $27.33M |
| Net Receivables | $13.88M | $8.70M | $9.14M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $3.32M | $2.73M | $151.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Assets | $13.41M | $11.18M | $12.01M | $8.09M | $8.93M | $7.75M | $6.90M | $4.21M | $5.61M | $6.17M | $7.64M | $4.64M | $5.06M | $6.15M | $6.03M | $115.00K | $1.34M | $- |
| Total Current Assets | $562.33M | $581.00M | $383.16M | $326.03M | $375.27M | $405.54M | $449.78M | $322.39M | $347.87M | $380.51M | $402.50M | $267.37M | $289.37M | $303.31M | $316.02M | $158.75M | $45.07M | $27.33M |
| Property Plant Equipment Net | $4.71M | $3.48M | $360.00K | $444.00K | $560.00K | $655.00K | $713.00K | $688.00K | $719.00K | $899.00K | $1.06M | $246.00K | $284.00K | $335.00K | $386.00K | $435.00K | $483.00K | $- |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $15.63M | $16.22M | $16.80M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $15.63M | $16.22M | $16.80M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $121.00K | $117.00K | $117.00K | $167.00K | $214.00K | $7.99M | $259.00K | $487.00K | $469.00K | $449.00K | $484.00K | $165.00K | $169.00K | $137.00K | $126.00K | $1.69M | $107.00K | $-27.33M |
| Total Non-Current Assets | $20.46M | $19.81M | $17.28M | $611.00K | $774.00K | $8.64M | $972.00K | $1.18M | $1.19M | $1.35M | $1.54M | $411.00K | $453.00K | $472.00K | $512.00K | $2.12M | $590.00K | $-27.33M |
| Other Assets | $- | $- | $1 | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $582.79M | $600.81M | $400.44M | $326.64M | $376.05M | $414.18M | $450.76M | $323.56M | $349.06M | $381.86M | $404.05M | $267.78M | $289.82M | $303.78M | $316.54M | $160.88M | $45.66M | $- |
| Account Payables | $3.26M | $3.02M | $6.44M | $4.78M | $2.58M | $3.39M | $4.57M | $4.66M | $260.00K | $3.97M | $439.00K | $701.00K | $1.74M | $683.00K | $348.00K | $686.00K | $202.00K | $- |
| Short Term Debt | $20.00K | $154.00K | $380.00K | $300.00K | $816.00K | $874.00K | $856.00K | $834.00K | $405.00K | $924.00K | $854.00K | $342.00K | $204.00K | $404.00K | $402.00K | $199.00K | $198.00K | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $1.55M | $1.46M | $- | $- | $25.48M | $20.24M | $19.33M | $- | $- | $- | $11.77M | $- | $6.61M | $4.98M | $4.02M | $2.17M | $1.57M | $- |
| Other Current Liabilities | $68.61M | $35.11M | $86.88M | $24.76M | $26.12M | $20.21M | $19.09M | $17.36M | $15.95M | $13.37M | $11.51M | $7.13M | $6.71M | $4.96M | $3.91M | $2.18M | $1.60M | $- |
| Total Current Liabilities | $73.45M | $39.74M | $93.71M | $29.84M | $29.51M | $24.48M | $24.51M | $22.85M | $16.61M | $18.27M | $12.80M | $8.18M | $8.66M | $6.05M | $4.66M | $3.07M | $2.00M | $- |
| Long Term Debt | $2.59M | $2.54M | $- | $- | $- | $77.00K | $190.00K | $300.00K | $408.00K | $514.00K | $617.00K | $- | $16.00K | $65.00K | $112.00K | $159.00K | $204.00K | $- |
| Deferred Revenue Non-Current | $3.23M | $3.06M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $761.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $221.72M | $91.96M | $-25.32M |
| Total Non-Current Liabilities | $6.59M | $5.60M | $- | $- | $- | $77.00K | $190.00K | $300.00K | $408.00K | $514.00K | $617.00K | $872.00K | $16.00K | $65.00K | $112.00K | $221.88M | $92.17M | $-25.32M |
| Other Liabilities | $- | $- | $- | $- | $- | $793.70M | $- | $- | $- | $- | $- | $-872.00K | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $80.04M | $45.34M | $93.71M | $29.84M | $29.51M | $818.25M | $24.70M | $23.15M | $17.02M | $18.79M | $13.42M | $8.18M | $8.67M | $6.11M | $4.77M | $224.95M | $94.16M | $-25.32M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $303.78M | $- | $4.78M | $- | $30.50M |
| Common Stock | $10.00K | $10.00K | $9.00K | $9.00K | $9.00K | $9.00K | $9.00K | $7.00K | $7.00K | $7.00K | $7.00K | $6.00K | $6.00K | $6.00K | $6.00K | $2.00M | $2.00M | $- |
| Retained Earnings | $-554.08M | $-488.37M | $-525.40M | $-521.00M | $-458.58M | $-404.07M | $-357.92M | $-312.06M | $-269.67M | $-229.56M | $-191.76M | $-155.23M | $-127.49M | $-105.55M | $-86.31M | $-72.02M | $-56.84M | $- |
| Accumulated Other Comprehensive Income Loss | $84.00K | $-6.00K | $-22.00K | $-5.00K | $9.00K | $-7.00K | $-9.00K | $67.00K | $-71.00K | $-392.00K | $-3.00K | $- | $- | $-303.78M | $- | $- | $- | $-10.67M |
| Other Total Stockholders Equity | $1.06B | $1.04B | $832.15M | $817.80M | $805.11M | $793.70M | $783.98M | $612.40M | $601.77M | $593.02M | $582.39M | $414.83M | $408.63M | $707.00M | $398.06M | $-3.61M | $92.60M | $5.49M |
| Total Stockholders Equity | $502.75M | $555.46M | $306.73M | $296.81M | $346.54M | $-404.07M | $426.05M | $-312.06M | $332.04M | $363.08M | $390.63M | $259.60M | $-127.49M | $297.67M | $311.76M | $-68.85M | $-54.20M | $25.32M |
| Total Equity | $502.75M | $555.46M | $306.73M | $296.81M | $346.54M | $-404.07M | $426.05M | $-312.06M | $332.04M | $363.08M | $390.63M | $259.60M | $- | $- | $- | $- | $- | $25.32M |
| Total Liabilities and Stockholders Equity | $582.79M | $600.81M | $400.44M | $326.64M | $376.05M | $414.18M | $450.76M | $-288.91M | $349.06M | $381.86M | $404.05M | $267.78M | $-118.81M | $303.78M | $316.54M | $160.88M | $45.66M | $- |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $316.54M | $4.78M | $5.70M | $- |
| Total Liabilities and Total Equity | $582.79M | $600.81M | $400.44M | $326.64M | $376.05M | $414.18M | $450.76M | $-288.91M | $349.06M | $381.86M | $404.05M | $267.78M | $-118.81M | $303.78M | $316.54M | $160.88M | $45.66M | $- |
| Total Investments | $406.75M | $135.62M | $122.25M | $47.55M | $135.56M | $164.36M | $253.67M | $268.91M | $257.01M | $253.48M | $5.99M | $- | $- | $- | $- | $- | $- | $- |
| Total Debt | $2.60M | $2.62M | $190.00K | $300.00K | $408.00K | $514.00K | $618.00K | $717.00K | $813.00K | $976.00K | $1.04M | $171.00K | $220.00K | $267.00K | $313.00K | $358.00K | $402.00K | $- |
| Net Debt | $-122.37M | $-420.15M | $-239.43M | $-270.09M | $-230.38M | $-240.66M | $-188.59M | $-48.55M | $-84.45M | $-119.89M | $-387.83M | $-262.56M | $-284.09M | $-296.89M | $-309.68M | $-154.51M | $-43.33M | $- |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-95.50M | $-188.92M | $-142.18M | $-72.75M | $-43.84M |
| Depreciation and Amortization | $1.56M | $383.00K | $531.00K | $199.00K | $155.00K |
| Deferred Income Tax | $- | $- | $- | $- | $- |
| Stock Based Compensation | $48.26M | $39.34M | $27.24M | $13.32M | $526.00K |
| Change in Working Capital | $- | $9.42M | $6.56M | $2.69M | $-357.00K |
| Accounts Receivables | $-13.88M | $- | $- | $- | $- |
| Inventory | $-3.24M | $- | $- | $- | $- |
| Accounts Payables | $686.00K | $2.32M | $-1.48M | $1.54M | $132.00K |
| Other Working Capital | $- | $7.10M | $8.05M | $1.15M | $-489.00K |
| Other Non Cash Items | $-32.44M | $-7.08M | $-2.03M | $8.00M | $30.03M |
| Net Cash Provided by Operating Activities | $-78.11M | $-146.85M | $-109.87M | $-48.54M | $-13.49M |
| Investments in Property Plant and Equipment | $-2.17M | $-224.00K | $-26.00K | $-8.00M | $-92.00K |
| Acquisitions Net | $- | $- | $255.05K | $- | $- |
| Purchases of Investments | $-658.62M | $-443.84M | $-394.21M | $- | $- |
| Sales Maturities of Investments | $393.89M | $575.44M | $139.16M | $- | $- |
| Other Investing Activities | $35.90M | $-3.00M | $-255.05K | $-8.00M | $- |
| Net Cash Used for Investing Activities | $-230.99M | $128.38M | $-255.07M | $-8.00M | $-92.00K |
| Debt Repayment | $- | $- | $- | $- | $- |
| Common Stock Issued | $178.18M | $161.41M | $161.61M | $167.04M | $29.98M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $25.11M | $5.18M | $4.29M | $130.07M | $29.98M |
| Net Cash Used Provided by Financing Activities | $203.29M | $164.00M | $165.90M | $297.12M | $29.98M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $-105.82M | $145.52M | $-199.05M | $240.58M | $16.40M |
| Cash at End of Period | $124.97M | $230.78M | $85.26M | $284.31M | $43.73M |
| Cash at Beginning of Period | $230.78M | $85.26M | $284.31M | $43.73M | $27.33M |
| Operating Cash Flow | $-78.11M | $-146.85M | $-109.87M | $-48.54M | $-13.49M |
| Capital Expenditure | $-2.17M | $-3.22M | $-26.00K | $-8.00M | $-92.00K |
| Free Cash Flow | $-80.28M | $-150.08M | $-109.90M | $-56.54M | $-13.58M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-65.71M | $37.04M | $-4.41M | $-62.41M | $-54.51M | $-46.15M | $-45.86M | $-42.39M | $-40.11M | $-37.80M | $-36.53M | $-27.75M | $-21.94M | $-19.24M | $-15.47M | $-16.10M | $-35.60M | $-3.84M | $-2.41M | $-1.99M |
| Depreciation and Amortization | $759.00K | $746.00K | $408.00K | $116.00K | $103.00K | $99.00K | $92.00K | $89.00K | $180.00K | $165.00K | $133.00K | $53.00K | $51.00K | $50.00K | $49.00K | $49.00K | $49.00K | $46.00K | $46.00K | $14.00K |
| Deferred Income Tax | $- | $- | $- | $- | $41.58M | $-45.79M | $4.22M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-578.00K | $270.00K | $90.00K | $218.00K |
| Stock Based Compensation | $11.04M | $11.55M | $13.03M | $12.64M | $10.81M | $9.61M | $9.48M | $9.45M | $6.83M | $8.58M | $5.63M | $6.20M | $5.10M | $5.15M | $2.54M | $538.00K | $350.00K | $60.00K | $57.00K | $59.00K |
| Change in Working Capital | $26.73M | $-52.21M | $50.74M | $1.22M | $3.80M | $-975.00K | $-879.00K | $7.47M | $-1.22M | $6.87M | $979.00K | $-71.00K | $3.64M | $1.82M | $-525.00K | $-2.24M | $-167.00K | $-121.00K | $317.00K | $-386.00K |
| Accounts Receivables | $-5.18M | $441.00K | $-9.14M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $-560.00K | $-2.55M | $-129.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $245.00K | $-3.43M | $1.66M | $2.20M | $-815.00K | $-1.17M | $-74.00K | $4.38M | $-3.71M | $3.53M | $-262.00K | $-1.04M | $1.06M | $338.00K | $-339.00K | $484.00K | $-171.00K | $148.00K | $112.00K | $43.00K |
| Other Working Capital | $32.23M | $-46.67M | $58.34M | $-989.00K | $4.62M | $199.00K | $-805.00K | $3.09M | $2.50M | $3.34M | $1.24M | $972.00K | $2.58M | $1.48M | $-186.00K | $-2.72M | $4.00K | $-269.00K | $205.00K | $-429.00K |
| Other Non Cash Items | $-2.82M | $53.62M | $-96.72M | $9.38M | $-43.15M | $46.15M | $-9.48M | $-599.00K | $-999.00K | $-1.03M | $-262.00K | $- | $-19.00K | $5.00K | $7.00K | $8.01M | $30.01M | $9.00K | $10.00K | $3.00K |
| Net Cash Provided by Operating Activities | $-30.01M | $50.75M | $-49.13M | $-49.73M | $-41.37M | $-37.06M | $-42.43M | $-25.98M | $-35.31M | $-23.21M | $-29.79M | $-21.56M | $-13.17M | $-12.22M | $-13.41M | $-9.74M | $-5.94M | $-3.58M | $-1.89M | $-2.08M |
| Investments in Property Plant and Equipment | $-1.42M | $-724.00K | $-17.13M | $- | $-8.00K | $-3.04M | $-149.00K | $-26.00K | $- | $-4.00K | $-7.00K | $-15.00K | $8.00M | $- | $- | $-8.00M | $1.00K | $- | $-5.00K | $-88.00K |
| Acquisitions Net | $- | $- | $- | $- | $-2.99M | $3.00M | $-20.42K | $11.17K | $- | $-20.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $-275.22M | $-214.63M | $-121.60M | $-47.16M | $-99.14M | $-79.96M | $-104.73M | $-160.01M | $-121.37M | $-266.85M | $-5.99M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $7.00M | $202.66M | $47.78M | $136.45M | $129.53M | $171.91M | $125.15M | $148.85M | $119.16M | $20.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $-55.00M | $108.00M | $89.29M | $2.99M | $-3.00M | $20.42K | $-11.17K | $-2.21K | $20.00M | $-5.99M | $- | $-8.00M | $- | $- | $- | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $-269.64M | $-67.70M | $17.06M | $89.29M | $30.38M | $88.92M | $20.27M | $-11.19M | $-2.21M | $-246.85M | $-6.00M | $-15.00K | $8.00M | $- | $- | $-8.00M | $1.00K | $- | $-5.00K | $-88.00K |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $178.18M | $1.30M | $48.00K | $597.00K | $115.00K | $162.10M | $1.18M | $1.92M | $2.05M | $- | $- | $167.66M | $-615.00K | $- | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $1.25M | $- | $- | $- | $- | $- | $- | $- | $318.00K | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $1.85M | $21.92M | $1.30M | $48.00K | $597.00K | $115.00K | $162.10M | $1.18M | $1.92M | $2.05M | $161.93M | $- | $318.00K | $- | $168.53M | $128.88M | $29.98M | $- | $- | $- |
| Net Cash Used Provided by Financing Activities | $1.85M | $200.09M | $1.30M | $48.00K | $597.00K | $115.00K | $162.10M | $1.18M | $1.92M | $2.05M | $161.93M | $- | $318.00K | $-615.00K | $168.53M | $128.88M | $29.98M | $- | $- | $- |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $228.58M | $-98.12M | $-130.47M | $- | $- | $- | $- | $- | $-8.00M | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $-297.80M | $183.15M | $-30.77M | $39.61M | $-10.39M | $51.97M | $139.94M | $-35.99M | $-35.60M | $-268.01M | $126.15M | $-21.58M | $-12.85M | $-12.84M | $155.13M | $111.14M | $24.04M | $-3.58M | $-1.89M | $-2.17M |
| Cash at End of Period | $124.97M | $422.76M | $239.62M | $270.39M | $230.78M | $241.18M | $189.21M | $49.27M | $85.26M | $120.86M | $388.88M | $262.73M | $284.31M | $297.16M | $310.00M | $154.87M | $43.73M | $19.69M | $23.27M | $25.16M |
| Cash at Beginning of Period | $422.76M | $239.62M | $270.39M | $230.78M | $241.18M | $189.21M | $49.27M | $85.26M | $120.86M | $388.88M | $262.73M | $284.31M | $297.16M | $310.00M | $154.87M | $43.73M | $19.69M | $23.27M | $25.16M | $27.33M |
| Operating Cash Flow | $-30.01M | $50.75M | $-49.13M | $-49.73M | $-41.37M | $-37.06M | $-42.43M | $-25.98M | $-35.31M | $-23.21M | $-29.79M | $-21.56M | $-13.17M | $-12.22M | $-13.41M | $-9.74M | $-5.94M | $-3.58M | $-1.89M | $-2.08M |
| Capital Expenditure | $-1.42M | $-55.72M | $-17.13M | $- | $-8.00K | $-3.04M | $-149.00K | $-26.00K | $- | $-4.00K | $-7.00K | $-15.00K | $8.00M | $- | $- | $-8.00M | $1.00K | $- | $-5.00K | $-88.00K |
| Free Cash Flow | $-31.43M | $-4.97M | $-66.25M | $-49.73M | $-41.38M | $-40.10M | $-42.58M | $-26.01M | $-35.31M | $-23.22M | $-29.79M | $-21.58M | $-5.17M | $-12.22M | $-13.41M | $-17.74M | $-5.94M | $-3.58M | $-1.89M | $-2.17M |
Day One Biopharmaceuticals Dividends
Explore Day One Biopharmaceuticals's dividend history, including dividend yield, payout ratio, and historical payments.
Day One Biopharmaceuticals News
Read the latest news about Day One Biopharmaceuticals, including recent articles, headlines, and updates.
Day One to Report First Quarter 2025 Financial Results Tuesday, May 6, 2025
BRISBANE, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Tuesday, May 6, 2025 at 4:30 p.m. ET to report financial results and discuss corporate progress for the first quarter 2025.
Investing in the $532B Oncology Boom: Key Stocks Shaping the Future of Cancer Treatment
The global oncology drug market, valued at over $200 billion today, is on pace to reach $532 billion by 2031-a growth story driven not just by rising demand but by genuine innovation. After years of incremental progress, new therapies like antibody-drug conjugates (ADCs) and immunotherapies are making strides against some of oncology's toughest challenges: rare pediatric cancers, relapsed tumors, and diseases like osteosarcoma, where survival rates have barely improved in decades. Regulators are helping accelerate this progress with tools like accelerated approvals and breakthrough designations that are shortening development timelines. At the same time, approaches like comparative oncology-using naturally occurring canine cancers as research models-are providing faster, more clinically relevant data than traditional preclinical studies. This convergence of scientific advancement and commercial opportunity is creating a market that's evolving faster than ever before. aAdsList.push('Article'); aAdsListSize.push([300, 250]); aAdsListCA.push(null); Within this expanding landscape, several companies are at the forefront of pioneering new treatments. Let's take a closer look at how some of the most innovative players in this space are tackling these pressing challenges.OS Therapies (NYSE-A: OSTX) is focused on transforming the treatment landscape for osteosarcoma, a rare and aggressive bone cancer that primarily affects children and young adults. The company's lead drug, OST-HER2, is a novel off-the-shelf immunotherapy that uses a modified form of Listeria bacteria to stimulate the immune system to target and destroy cancer cells that express the HER2 protein. Recent data has further validated the potential of OST-HER2 in treating osteosarcoma. New unpublished research shows that when combined with palliative radiation, OST-HER2 has had a significant impact on dogs with unresected, primary osteosarcoma. Out of 15 dogs treated, 5 experienced survival times exceeding 500 days, with clinical and radiographic arrest of the primary tumor and delayed pulmonary metastases. These findings could have profound implications for the potential use of OST-HER2 as a frontline therapy in humans, potentially before chemotherapy is even considered. This approach could reduce or even eliminate the need for surgery and chemotherapy, offering a more effective and less invasive treatment alternative for patients. This data complements previous research published in the journal Molecular Therapy, which demonstrated how OST-HER2 induces strong immune responses from the very first dose. These responses were shown to correlate with both the prevention of metastasis and long-term survival in dogs that had undergone surgery to remove their primary osteosarcoma. Additionally, the study showed that dogs who initially had weaker immune responses showed significant improvement after the second and third doses, supporting the use of repeated dosing as a potential strategy for treating the disease. The combination of these results marks a critical milestone in OS Therapies' development of OST-HER2. The company is now preparing to submit this new data to the USDA, along with information on their improved manufacturing process, aiming for conditional approval in the United States by 2025. Following this, OS Therapies plans to conduct a pivotal clinical study with the goal of gaining full approval for the treatment by 2026. The company is also on track to secure FDA Accelerated Approval for OST-HER2 in human osteosarcoma, with plans to submit an application by the end of 2025. If approved, OST-HER2 could be one of the first treatments to offer a meaningful improvement in survival for patients with this rare and difficult-to-treat cancer. Moreover, a successful approval would make OS Therapies eligible for a Priority Review Voucher (PRV), which could be sold for a significant financial gain, providing the company with the resources needed to fund future projects. As OS Therapies continues to advance in both human and veterinary applications, its approach to Comparative Oncology is proving to be a game-changer. With a 96% genetic similarity between human and canine osteosarcoma, research in dogs with osteosarcoma offers valuable insights that could accelerate the development of new therapies for humans. OS Therapies is leveraging this unique advantage to not only improve treatments for dogs but also to push the boundaries of cancer treatment in humans. Financially, OS Therapies remains well-positioned for the future. The company raised $12 million in 2024 through an IPO and private placement, and it expects its cash reserves to last through mid-2026. With clinical costs now tapering off as the company moves forward in its regulatory journey, OS Therapies is in a solid position to continue advancing its pipeline without needing to raise additional capital in the near term. The company's growth isn't limited to just one drug. Beyond OST-HER2, OS Therapies is also working on an innovative antibody-drug conjugate (ADC) platform, which could allow for custom-designed cancer treatments tailored to various cancers. This growing pipeline positions OS Therapies as a company to watch in the biotech space, offering not only a potential breakthrough in osteosarcoma treatment but also future opportunities in oncology. As the company works toward Accelerated Approval for OST-HER2 by the end of 2025, the potential for significant regulatory milestones, a potential PRV sale, and an expanding clinical pipeline make OS Therapies a standout in the emerging biotech field. Investors, clinicians, and patients alike should keep a close eye on this company as it continues to push forward in the fight against osteosarcoma and other forms of cancer.Day One Biopharmaceuticals (Nasdaq: DAWN) is gaining traction in the pediatric oncology world with OJEMDA (tovorafenib), its lead treatment for children with low-grade glioma (pLGG), a rare brain cancer. OJEMDA is a Type II RAF kinase inhibitor that targets BRAF alterations, which are often found in pLGG patients. It received FDA approval under the accelerated approval pathway, and the early numbers suggest strong adoption-more than 1,600 prescriptions were written in the eight months following its April 2024 launch. Full-year net product revenue came in at $57.2 million, with $29 million in the fourth quarter alone. In late 2024, OJEMDA also earned the "Exclusively Pediatric" designation from CMS, lowering its Medicaid and 340B rebate obligations, which could help margins moving forward. The drug is currently at the center of Day One's pipeline, with the Phase 3 FIREFLY-2 study ongoing. The company expects to complete enrollment by mid-2026. Beyond OJEMDA, Day One is working to expand its reach in pediatric cancer. DAY301, an antibody-drug conjugate (ADC) targeting PTK7, has cleared its first dosing cohort in a Phase 1a/b trial. If development goes well, it could become a valuable second asset alongside OJEMDA. From a financial standpoint, Day One ended 2024 with $531.7 million in cash and equivalents, giving the company plenty of runway. While the full-year net loss totaled $95.5 million-largely due to R&D and launch costs-the company continues to invest in growth. R&D expenses jumped to $227.7 million in 2024, up from $130.5 million in 2023, driven by the advancement of DAY301 and other pipeline efforts. Even with the losses, Day One is in a strong position: OJEMDA is gaining traction, the pipeline is moving, and the balance sheet is healthy. For anyone watching the space, Day One stands out as a biotech laser-focused on filling a serious treatment gap in pediatric cancer.GSK plc (NYSE: GSK) is making real moves in oncology, especially in tough-to-treat cancers like osteosarcoma. In January, the FDA gave Breakthrough Therapy Designation to one of GSK's experimental antibody-drug conjugates (ADCs) that targets B7-H3-a protein linked to tumor growth. The drug showed early promise in a mid-stage trial for patients with relapsed or refractory osteosarcoma who've already gone through two lines of treatment. That's a big deal in a space with no currently approved therapies for patients at that stage. Osteosarcoma mostly affects children and young adults, and once it comes back after initial treatment, the outlook gets bleak. GSK's drug could help fill that gap. The company is now running a global trial aimed at eventually getting the treatment approved more broadly. On the business side, GSK is firing on all cylinders. In February the company launched a $2.5 billion stock buyback after a strong Q4 and raised its long-term revenue forecast. Oncology is now a major focus for GSK's pipeline, along with respiratory diseases, HIV, and other specialty areas. With five product approvals expected this year-including a relaunch of its blood cancer drug Blenrep-the company looks well-positioned to keep growing in high-need treatment areas.ADC Therapeutics (NYSE: ADCT) stands out as a promising player in the antibody drug conjugate (ADC) space, focusing on the treatment of hematologic malignancies and solid tumors. With a proprietary ADC technology platform, the company is positioning itself to make a significant impact in oncology. Investors looking for growth potential in this innovative field should take note of ADC Therapeutics, particularly with its lead product, ZYNLONTA (loncastuximab tesirine). Recent clinical trial results further solidify the company's growth trajectory. In December 2024, ADC Therapeutics published updated data from a Phase 2 clinical trial evaluating ZYNLONTA in combination with rituximab for treating relapsed or refractory follicular lymphoma (FL). The results showed a robust 97.4% overall response rate and 76.9% complete response rate, positioning ZYNLONTA as a strong treatment option for high-risk FL patients. These results were published in The Lancet Haematology and presented at the prestigious American Society of Hematology (ASH) Annual Meeting, raising the company's profile in the oncology field. With progression-free survival remaining strong at 94.6% at 12 months, the long-term potential for ZYNLONTA in treating indolent B-cell lymphomas is clear. Additionally, ADC Therapeutics is making strides with the LOTIS-7 trial, which is evaluating ZYNLONTA in combination with glofitamab for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The initial data showed impressive results, with a 94% overall response rate and 72% complete response rate, alongside a manageable safety profile. This combination therapy could provide a competitive edge in the highly saturated DLBCL market, demonstrating the potential for ZYNLONTA beyond its initial indication. From a financial perspective, ADC Therapeutics reported stable revenues in Q4 2024, generating $16.4 million in product sales. Despite the flat revenue growth, the company is focused on reducing operating expenses, achieving a 13% year-over-year reduction. With $251 million in cash reserves at the end of 2024, the company is well-positioned to fund operations into the second half of 2026, allowing for continued investment in its clinical pipeline and commercial efforts. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by O S Therapies Inc to assist in the production and distribution of content related to OSTX. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Media Contact Company Name: RazorPitch Contact Person: Mark McKelvie Email: markrmckelvie@gmail.com City: NAPLES State: Florida Country: United States Website: https://razorpitch.com/ Source: www.abnewswire.com .(C) 2025 M2 COMMUNICATIONS, source M2 PressWIRE
Day One Biopharmaceuticals Pullback Is A Potential Buying Opportunity
Day One Biopharmaceuticals' Ojemda launched in Q2'24 and generated $57.2M in net product revenues in 2024. Despite reporting continued sales growth so far, DAWN's stock is near 52-week lows, perhaps in part due to a broader biotech sector pullback. A readout from the FIREFLY-2 trial of Ojemda might not be near-term, but does provide the potential for label expansion for those with a few quarters of patience.
Day One Biopharmaceuticals, Inc. (DAWN) Q4 2024 Earnings Call Transcript
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN ) Q4 2024 Earnings Conference Call February 25, 2025 4:30 PM ET Company Participants Joey Perrone - SVP, Finance and IR Jeremy Bender - CEO Lauren Merendino - CCO Charles York - COO and CFO Conference Call Participants Andrea Newkirk - Goldman Sachs Tara Bancroft - TD Cowen Joe Catanzaro - Piper Sandler Alec Stranahan - Bank of America Andres Maldonado - H.C. Wainwright Operator Hello, ladies and gentlemen, and welcome to the Day One Biopharmaceuticals Fourth Quarter and Full Year 2024 Financial and Operating Results Conference Call.
Does Day One Biopharmaceuticals (DAWN) Have the Potential to Rally 193.16% as Wall Street Analysts Expect?
The mean of analysts' price targets for Day One Biopharmaceuticals (DAWN) points to a 193.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Day One to Report Fourth Quarter and Full-Year 2024 Financial Results Tuesday, February 25, 2025
BRISBANE, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Tuesday, February 25, 2025 at 4:30 p.m.
Top 5 Commercial Biotech Buyout Candidates: Day One Biopharmaceuticals (No. 5)
Day One Biopharmaceuticals focuses on pediatric cancer treatments, with a promising pipeline including tovorafenib and other targeted therapies. The stock has experienced a bearish trend but has significant upside potential, with Wall Street targeting a 190% increase. Strong financial position with $558.4M in cash and a cash runway of over 3 years significantly reducing the dilution risk.
Day One Biopharmaceuticals: Sales Figures In The Crosshairs
Day One Biopharmaceuticals' key asset, tovorafenib, shows promise in treating pediatric low-grade glioma, with ongoing phase 3 trials aiming to expand its use. DAWN's financial health is strong, with $422.8 million in cash and equivalents, ensuring sustainability for over two years despite a net loss excluding licensing revenue. The company's deep cash reserves and promising pipeline, including the new DAY301 agent, provide a solid foundation for future growth and drug development.
Day One to Present at the 43rd Annual J.P. Morgan Healthcare Conference
BRISBANE, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Dr. Jeremy Bender, chief executive officer, will present during the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13 at 3:45 p.m. Pacific Time / 6:45 p.m. Eastern Time.
Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development
Dr. Blackman's departure planned for end of 2024 Company's search for a new Head of R&D is ongoing BRISBANE, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Samuel Blackman, M.D.
Day One to Participate in the Piper Sandler 36th Annual Healthcare Conference
BRISBANE, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3 at 3:00 p.m. EST.
Wall Street Analysts See a 136.83% Upside in Day One Biopharmaceuticals (DAWN): Can the Stock Really Move This High?
The mean of analysts' price targets for Day One Biopharmaceuticals (DAWN) points to a 136.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Day One Biopharmaceuticals, Inc. (DAWN) Q3 2024 Earnings Call Transcript
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN ) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Joey Perrone - SVP, Finance and IR Jeremy Bender - CEO Lauren Merendino - CCO Samuel Blackman - Co-Founder and Head, R&D Charles York - COO and CFO Conference Call Participants Anupam Rama - JPMorgan Joe Catanzaro - Piper Sandler Andrea Newkirk - Goldman Sachs Soumit Roy - Jones Research Alec Stranahan - Bank of America Ami Fadia - Needham & Company Andres Maldonado - H.C. Wainwright Operator Hello, ladies and gentlemen, and welcome to the Day One Biopharmaceuticals' Third Quarter of 2024 Financial and Operating Results Conference Call.
Day One Reports Third Quarter 2024 Financial Results and Corporate Progress
Achieved $20.1 million in OJEMDA TM (tovorafenib) net product revenue Ended the third quarter with $558.4 million in cash, cash equivalents and short-term investments Company to host conference call and webcast today, October 30, 4:30 p.m. Eastern Time BRISBANE, Calif.
Wall Street Analysts Think Day One Biopharmaceuticals (DAWN) Could Surge 140.71%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 140.7% in Day One Biopharmaceuticals (DAWN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Day One to Report Third Quarter 2024 Financial Results Wednesday, October 30, 2024
BRISBANE, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Wednesday, October 30, 2024 at 4:30 p.m. ET to report financial results and discuss corporate progress for the third quarter 2024.
Day One Announces Oversubscribed $175.0 Million Private Placement
BRISBANE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a commercial-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it has entered into a securities purchase agreement for an oversubscribed private placement of its securities for gross proceeds of approximately $175.0 million, before deducting placement agent fees and other expenses.
Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor
PARIS, FRANCE, and BRISBANE, CALIFORNIA U.S., 25 July 2024 - Ipsen (Euronext: IPN; ADR: IPSEY) and Day One Biopharmaceuticals (Nasdaq: DAWN) (Day One), announced today a new global partnership outside the U.S. for tovorafenib, an oral, once-weekly, type II RAF inhibitor for pediatric low grade glioma (pLGG), the most common form of childhood brain cancer, i and any future indications developed by Day One.
Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers
Day One receives exclusive license for development and commercialization of MTX-13 (DAY301), which received IND clearance by the FDA in April 2024
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for DAWN.